Category: Science Explained
Myo-inositol turns up on shelves as a calm-sounding supplement for cycles and blood sugar. It is a sugar alcohol that your cells use to relay the insulin signal. Here is the real definition, the second-messenger mechanism, and what the 40:1 ratio is actually about.
Category: Science Decoded | Reading time: ~8 min | Level: Intermediate
There is a particular kind of supplement that turns up in cycle-tracking forums and polycystic ovary syndrome groups long before it reaches the mainstream shelf, passed hand to hand as the gentle, unglamorous thing that quietly seemed to help. Myo-inositol is one of those. It has no exotic origin story and no marketing swagger. It is a sugar alcohol your own body already makes, and the reason it keeps coming up is that it sits at a specific point inside one of the most important signals your metabolism runs on.
The trouble is that the label rarely explains any of this. You see the word inositol, sometimes a ratio like 40:1, sometimes the old tag vitamin B8, and very little about what it actually does. So here is the plain version: what myo-inositol is, where it acts, what that 40:1 figure means, and how good the evidence really is.
Myo-inositol is a sugar alcohol, a naturally occurring carbohydrate that is closely related to glucose in its chemical shape but built into a ring with alcohol groups attached. Your body synthesises it from glucose, and you also take it in from foods such as fruit, beans, grains and nuts [1]. It is the most abundant of nine possible inositol isomers, which are molecules with the same atoms arranged differently.
Its job inside the body is to act as a raw material for signalling. When insulin arrives at a cell after a meal, the message has to be carried from the cell surface to the machinery inside. Myo-inositol is a precursor to a family of second-messenger molecules, the inositol phosphoglycans, that help relay that insulin signal onward [1]. That is the single mechanism sentence worth remembering: myo-inositol is a building block your cells use to pass the insulin message along.
Insulin does not enter a cell to do its work. It docks onto a receptor on the outside, and everything that follows happens through an internal relay. Second messengers are the couriers in that relay. Some of them are built on inositol, and myo-inositol supplies the backbone.
The proposed logic behind supplementing is straightforward. In tissues where the insulin signal is not being carried efficiently, a state loosely called insulin resistance, providing more myo-inositol may support the pathway that relays the signal [1]. In the ovary, insulin signalling influences how the follicle matures and how androgens are produced, which is why a molecule best known for blood sugar ends up mattering for menstrual cycles and ovulation.
This mechanism is described reasonably well in laboratory and physiological work. What is harder is predicting the size of the effect in any given person, because insulin signalling is influenced by weight, diet, genetics and much else. A plausible mechanism is a starting point, not a guarantee of a large clinical result.
If you shop for inositol you will keep meeting a number: 40:1. This refers to the balance between two isomers, myo-inositol and D-chiro-inositol.
D-chiro-inositol is made in the body from myo-inositol, and it plays its own, distinct part in insulin signalling. The two are present in different amounts in different tissues, and in blood plasma they sit at roughly a 40 to 1 ratio of myo to D-chiro [4]. Several supplements deliberately combine the two isomers at that same 40:1 ratio, on the reasoning that mirroring the body's natural plasma balance might work better than giving either isomer alone or in some arbitrary mix [4].
The honest position is that the 40:1 combination is widely used and reasonable in principle, but the claim that it clearly outperforms plain myo-inositol is still contested. Much of the human evidence base uses either myo-inositol on its own or the 40:1 blend, and head-to-head certainty is limited. If you see a wildly different ratio, that is worth a second look, because it is not the one the physiology or most of the research points to.
The clearest body of human evidence is in polycystic ovary syndrome, though even here it is far from settled. A Cochrane systematic review examined inositol in subfertile women with the condition and concluded that the evidence was of low quality and uncertain, flagging that the trials were often small and inconsistent [2]. A separate meta-analysis of randomised trials reported improvements in metabolic markers such as fasting insulin with myo-inositol [3]. Taken together, that is a moderate grade: a real and reasonably consistent signal, built on a trial base that is not yet large or uniformly rigorous.
Beyond that, the evidence thins. Myo-inositol has been studied for reducing the risk of gestational diabetes in higher-risk pregnancies and for anxiety and mood, but those areas rest on fewer and smaller studies, and none of it amounts to proof that the compound treats a disease. It is more accurate to say myo-inositol supports specific processes, insulin signalling and ovarian function among them, than to say it fixes a condition.
If you are looking at myo-inositol, the useful framing is metabolic and hormonal support with moderate evidence in one specific setting, not a cure-all. The doses used in polycystic ovary syndrome research typically sit in the low grams per day range, often split across the day, and effects on cycles and metabolic markers are assessed over roughly three to six months. That timescale matters: this is a slow, physiological nudge, and judging it after a week tells you nothing.
If you choose a product, look for one that names the isomer and states the dose, rather than one that simply says inositol. If you want the two-isomer approach, the 40:1 myo to D-chiro ratio is the one grounded in the physiology and the research. And match the studied dose rather than assuming more is better, because the main thing higher intakes reliably add is digestive upset.
If your interest is polycystic ovary syndrome specifically, our education piece on inositol for PCOS goes deeper into the trials and the practical questions to ask a clinician.
Myo-inositol is generally well tolerated in studies, with mild nausea, loose stools or bloating at higher doses being the usual complaints. That is a reassuring profile, but it comes with real limits. Long-term safety data are modest, and its use in pregnancy has mostly been confined to specific trial settings rather than established as routinely safe.
Because it acts inside the insulin pathway and can influence blood sugar handling, anyone taking medication for diabetes or a hormonal condition should treat it as something that could interact with their treatment and coordinate with the prescriber rather than adding it silently. This is a general caution drawn from how the compound works, not a claim about a specific verified drug pairing.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
We treat myo-inositol the way we treat every ingredient: by naming exactly what it does and refusing to inflate it. It is a sugar alcohol that supports insulin signalling, with its most credible human evidence in polycystic ovary syndrome, working over months rather than days. That is a genuinely useful thing to understand, and it is also a long way from the miracle framing these compounds sometimes attract.
If you want to go further, our inositol for PCOS education article lays out the studies and the questions worth raising with a clinician, and our explainer on how we grade evidence shows why a moderate grade here is a compliment, not a hedge. You can also browse the Remedy Library to see how we describe ingredients in plain, evidence-anchored terms.
1. Croze ML, Soulage CO (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie, 95(10), 1811 to 1827. Review of inositol biology, its synthesis from glucose, and its role as a precursor to insulin second messengers. 2. Showell MG, Mackenzie-Proctor R, Jordan V, et al. (2018). Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, (12), CD012378. Systematic review reporting uncertain, low-quality evidence, with trials that were often small and of variable quality. 3. Unfer V, Facchinetti F, Orru B, et al. (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomised controlled trials. Endocrine Connections, 6(8), 647 to 658. Reported improvements in fasting insulin and HOMA index. 4. Nordio M, Proietti E (2012). The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. European Review for Medical and Pharmacological Sciences, 16(5), 575 to 581. Basis for the 40:1 plasma-mirroring rationale.
It is a sugar alcohol, a type of carbohydrate closely related to glucose in structure, that occurs naturally in the body and in foods such as fruit, beans and grains. Inside cells it is turned into signalling molecules that help relay the message insulin sends after you eat. Because it sits inside the insulin pathway, it is studied most in conditions linked to insulin resistance. It is sometimes called vitamin B8, but that label is outdated because a healthy body can make its own.
When insulin binds to a cell, the message has to be carried onwards inside the cell. Myo-inositol is a building block for a group of second-messenger molecules, called inositol phosphoglycans, that help carry that insulin message. In tissues where insulin signalling is impaired, supplying more myo-inositol appears to support the pathway, which is the proposed reason it influences blood sugar and ovarian function. The mechanism is reasonably well described in laboratory work, though the size of the human effect varies.
Myo-inositol and D-chiro-inositol are two different isomers with different roles, and healthy blood plasma carries them in roughly a 40 to 1 ratio. Several supplements combine them at that ratio on the reasoning that it reflects the body's natural balance and may work better than either alone. The 40:1 formulation is common in polycystic ovary syndrome research, but whether it genuinely beats myo-inositol on its own is still debated.
Not really. It was once labelled vitamin B8, but a true vitamin is something the body cannot make in adequate amounts and must obtain from diet. A healthy body synthesises myo-inositol from glucose, so it does not meet the definition. It is better described as a vitamin-like compound or simply a sugar alcohol.
The best-studied use is in polycystic ovary syndrome, where it is taken for its effects on insulin sensitivity, menstrual regularity and ovulation. It has also been studied for gestational diabetes risk and for mood and anxiety, though that evidence is thinner. It is not a treatment for any diagnosed disease, and anyone with a medical condition should speak to a clinician before starting.
In studies it is generally well tolerated, with mild digestive upset such as nausea or loose stools at higher doses being the most common complaint. Long-term safety data are limited, and it has not been well studied in pregnancy outside specific trial settings. Because it can affect blood sugar handling, anyone on medication for diabetes or a hormonal condition should check with a healthcare professional first.
In polycystic ovary syndrome trials, effects on cycle regularity and metabolic markers are typically assessed over roughly three to six months, not days. It is a slow, physiological effect rather than an acute one, so a fair trial is measured in cycles rather than in a single week.
It can. Inositol on a label usually means myo-inositol, which is by far the most abundant form, but the word alone does not confirm the isomer or the dose. Because myo-inositol and D-chiro-inositol behave differently, and much of the human research uses specific doses of myo-inositol or a defined 40:1 blend, a product that simply says inositol without a quantity tells you less than one that names the isomer and states milligrams per serving.
Because its clearest biological role sits inside the insulin signalling pathway, and the conditions where it has been studied most, such as polycystic ovary syndrome and gestational diabetes risk, are ones tied to insulin handling. That is a structure and function description of where it acts, not a claim that it treats those conditions. The research clustering there is why you see it discussed alongside metabolic and hormonal topics rather than as a broad daily supplement.
Not automatically. Trials tend to use doses in a defined range rather than escalating without limit, and higher intakes mainly raise the chance of digestive side effects rather than adding benefit. As with most supplements studied at a specific dose, the sensible move is to match the dose the research used rather than to assume more delivers more.